Menagen–CKD Middle Eastern partnership

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Menagen–CKD Middle Eastern partnership

Home/Pharma News | Posted 03/09/2021 0

Omani company, Menagen Pharmaceutical Industries and Korean company, Chong Kun Dang Pharmaceutical Corp (CKD), have formed a strategic partnership to provide biosimilars to countries in the Middle East.

The partnership, which was announced in July 2021, will allow the export of CKD’s Nesbell (darbepoetin alfa), an anaemia treatment biosimilar, to six countries in the Middle East: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates.

Darbepoetin alfa is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anaemia, commonly associated with chronic renal failure and cancer chemotherapy [1]. The originator product is Amgen’s Aranesp, which was approved in the US and Europe in 2001.

CKD’s Nesbell, was released in Korea and Japan in 2019 [1, 2]. It was co-developed by Japan’s Kyowa Hakko Kirin and the US’s Amgen. It is a second-generation anaemia biosimilar therapy and, compared to the first generation of drugs, the treatment significantly reduces the frequency of drug administration by using genetic engineering techniques.

Lotus to distribute CKD’s biosimilar darbepoetin alfa in South East Asia

LATIN AMERICAN FORUM The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: Biosimilares e intercambiabilidad en oncología Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: Biosimilares e intercambiabilidad en oncología Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of darbepoetin alfa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-darbepoetin-alfa
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.